Christine Simmon Discusses AAM Efforts for Biosimilar Legislation

We sat down with Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the AAM, to discuss some of the advocacy changes the organization is looking to advance and their chances of approval. 
June 14, 2020
Biosimilar manufacturers have to overcome many hurdles in order for their products to be successful in the US market. Some of those hurdles are systemic, such as reimbursement systems that eliminate incentives for physicians to prescribe biosimilars. Some are through direct actions by reference manufacturers to prevent competition, such as patent thickets. And some limit savings for patients, such as cost sharing. However, advocacy groups such as the Association for Accessible Medicines, or AAM, are looking to change things on a legislative level.

We sat down with Christine Simmon, executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the AAM, to discuss some of the advocacy changes the organization is looking to advance and their chances of approval. 



To learn more about the AAM, visit accessiblemeds.org.

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.